Method of inhibiting the activity of human immunodeficiency viru

Details Method of inhibiting the activity of human immunodeficiency viru Method of inhibiting the activity of human immunodeficiency viru

1992-12-10

1994-01-11

Nutter, Nathan M.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514885, 514895, A01N 4342, A61K 3147

Patent

active

052781739

ABSTRACT:
A method for inhibiting the activity of human immunodeficiency virus (HIV) in vivo comprises administering to a human host an antimalarial drug, which is capable of exhibiting a protective effect, a curative effect, or of preventing transmission of malaria in humans. The antimalarial drug is selected from the group consisting of

REFERENCES:
patent: 4835140 (1989-05-01), Smith et al.
patent: 4970212 (1990-11-01), Nowicky
patent: 5061715 (1991-10-01), Sunkara et al.
The Merck Index; Susan Budavari, ed; Merck & Co. Rahway, New Jersey, 1989, pp. 89 #602.
Kay et al., Southern Medical Journal, vol. 86, No. 4 pp. 403-404, Apr. 1990 "Clindamycin/Primaquine Therapy and Secondary Prophylaxis Against Pneumocystis carinii Pneumonia in Patients with AIDS".
Black et al, Eur. J. Clin. Microbiol. Infect. Dis., vol. 10, 1991 pp. 204-213, "Clindamycin and Primaquine as Primary Treatment for Mild . . . AIDS".

Affiliated with

Also associated with

Rating

Method of inhibiting the activity of human immunodeficiency viru does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of inhibiting the activity of human immunodeficiency viru, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting the activity of human immunodeficiency viru will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1631561